Please login to the form below

Not currently logged in
Email:
Password:

Kazano

This page shows the latest Kazano news and features for those working in and with pharma, biotech and healthcare.

FDA investigates pancreas risk of diabetes drugs

FDA investigates pancreas risk of diabetes drugs

Newer DPP-4 inhibitors Tradjenta (linagliptin) from Boehringer Ingelheim and Takeda's alogliptin-based medicines (Nesina, Kazano and Oseni) are also affected.

Latest news

  • Takeda gets FDA approval for alogliptin franchise in diabetes Takeda gets FDA approval for alogliptin franchise in diabetes

    Takeda gets FDA approval for alogliptin franchise in diabetes. Comprises Nesina, Oseni and Kazano. ... The US agency approved Takeda's DPP-4 inhibitor Nesina (alogliptin) - along with two fixed-dose combination products Oseni (alogliptin and pioglitazone)

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics